Danni microvascolari nell'impotenza erettile di “origine psicogena”

1997 ◽  
Vol 64 (1_suppl) ◽  
pp. 103-109
Author(s):  
F. Albergati ◽  
P. Lattarulo ◽  
S.B. Curri ◽  
H. Jallous ◽  
C. Marandola ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Contractile Activity ◽  
Double Blind Study ◽  
Double Blind ◽  
Duration Of Action ◽  
Laser Doppler Flow ◽  
Doppler Flow ◽  
The Third ◽  
Erectile Impotence ◽  
Site Of Action

Erectile impotence is one of the major reasons for uro-andrological consultation. Countless experimental and clinical data are by now available regarding the importance of the pathologies of penile microcirculation as primitive cause of erectile dysfunction with the result that microangiological evaluation in andrology is being used more and more. Up to the present, however, there has been a lack of data related to the action of penile manipulation “in itself (necessary for correct topical application of substances with microvasculokinetic action) on the contractile activity of the arterioles examined by Laser-Doppler Flow. This report gives the results of a clinical study on 400 patients with erectile dysfunction treated with topically administered microvasculokinetic therapies. All the patients underwent a complete microangiological assessment to detect the presence of microcirculatory pathologies responsible for the erectile dysfunction. In a double blind study three different substances were used topically: two proved to nave microvasculokinetic activity with a different duration of action, while the third was totally inert. The first two increased the penile arteriolar contractile capacity in all the patients, while the third had no effect, showing that manipulation “in itself has no effect which helps increase penile arteriolar sphygmic activity. Furthermore, the different duration of action between the two substances acting on the microcirculation highlights the importance of using suitably complexed molecules for crossing the cutaneous barrier and reaching the site of action in patients who respond positively to the microvasculokinesis test.

scholarly journals Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience

2016 ◽  
Vol 10 (3) ◽  
pp. 171-187 ◽  
Author(s):  
Johan Virhammar ◽  
Dag Nyholm
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Evidence ◽  
Motor Fluctuations ◽  
Small Scale ◽  
Double Blind Study ◽  
Open Label ◽  
Double Blind ◽  
Duration Of Action ◽  
Substantial Impact

The duration of action of oral levodopa becomes shorter as Parkinson’s disease (PD) progresses. Patients with advanced PD may develop potentially disabling motor fluctuations and abnormal involuntary movement (dyskinesia), which cannot be managed with optimized oral or transdermal PD medications. The progressively worsening symptoms can have a substantial impact on the patient quality of life (QoL). Levodopa–carbidopa intestinal gel (LCIG) is delivered continuously via a percutaneous endoscopic gastrostomy with a jejunal extension (PEG-J). LCIG is licensed for the treatment of levodopa-responsive advanced PD in individuals experiencing severe motor fluctuations and dyskinesia when available combinations of antiparkinsonian medications have not given satisfactory results. Initial evidence for the efficacy and tolerability of LCIG came from a number of small-scale studies, but recently, three prospective studies have provided higher quality evidence. A 12-week double-blind comparison of LCIG with standard levodopa therapy, a 52-week open-label study extension of the double-blind study, and a 54-week open-label safety study, demonstrated significant improvements in ‘off’ time and ‘on’ time without troublesome dyskinesia, and QoL measures that were maintained in the longer term. There are also observations that LCIG may be effective treatment for nonmotor symptoms (NMS) although the evidence is limited. There is a need for further research on the efficacy of LCIG in reducing NMS, dyskinesia and improving QoL. This review surveys the clinical evidence for the effectiveness and tolerability of LCIG in the management of advanced PD and highlights some practical considerations to help optimize treatment.

Transient Neurologic Symptoms after Spinal Anesthesia 

1998 ◽  
Vol 88 (3) ◽  
pp. 629-633 ◽  
Author(s):  
Karl F. Hampl ◽  
Sidonie Heinzmann-Wiedmer ◽  
Igor Luginbuehl ◽  
Christoph Harms ◽  
Manfred Seeberger ◽  
...  
Keyword(s):  
Spinal Anesthesia ◽  
Surgical Procedures ◽  
Local Anesthetic ◽  
Spinal Block ◽  
Double Blind Study ◽  
Double Blind ◽  
Duration Of Action ◽  
Neurologic Symptoms ◽  
American Society ◽  
The Times

Background Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine. However, identification of a short-acting local anesthetic to substitute for lidocaine for brief surgical procedures remains an important goal. Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine. Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs. Methods Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose. All solutions were provided in blinded vials by the hospital pharmacy. Details of spinal puncture, extension and regression of spinal block, and the times to reach discharge criteria were noted. In the evening of postoperative day 1, patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure. Results Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs. Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05). Conclusions Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.

TREATMENT OF RAYNAUD SYNDROMES WITH PIRACETAM(NOOTROPIL R),NOOTROPIC AND ANIPLATELET AGENT

1987 ◽  
Author(s):  
M Moriau ◽  
E Lavenne-Pardonge ◽  
C H Col-De Beys
Keyword(s):  
Systemic Disease ◽  
The Other ◽  
Optimal Dosage ◽  
Double Blind Study ◽  
Inhibiting Activity ◽  
Synergic Effect ◽  
Double Blind ◽  
The Third ◽  
Daily Aspirin ◽  
Platelet Functions

Three prospective studies have been performed with piracetam (Nootropil ®-) in the treatment of Raynaud disease and syndromes.The first one, realized in 20 cases of Raynaud disease established that 8 g piracetam daily was the optimal dosage necessary to obtain a significant clinical, ultrasonic and biologic improvement.In the second one, 58 cases of Raynaud syndromes (47 idiopathic and 11 associated with systemic disease) were treated with 8 g daily piracetam during 6 to 12 months. A clinical and ultrasonic improvement was observed in 75 and 80 % of the cases and a normalisation of the disturbed platelet functions (36/58) in 88 %. Moreover a benefic rheologic effect was noted and related to the membrane deformability, the antiplatelet and the Von Willebranc factor synthese or release inhibiting activity of piracetamThe third one realized in cross over in 30 cases of Raynaud syndromes compare the effects of piracetam alone (dosage 8 g daily) with the combination piracetam (4 g daily) - aspirin (100 mg daily) or with other drugs like buflomedil, calcium antagonists and ketanserine.A synergic effect was obtained with the combination piracetam -aspirine and piracetam alone seems to be more efficient than the other drugs.A fourth double blind study is actually performed

scholarly journals Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes Mellitus

2012 ◽  
Vol 87 (9) ◽  
pp. 843-852 ◽  
Author(s):  
Irwin Goldstein ◽  
LeRoy A. Jones ◽  
Laurence H. Belkoff ◽  
Gary S. Karlin ◽  
Charles H. Bowden ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document